Functional Neurological Disorder (FND) involves neurological symptoms arising from brain network changes rather than structural damage, often described as a “software” issue rather than a “hardware” problem. Symptoms…
Pompe disease is a progressive, life-threatening genetic neuromuscular disorder. Late-onset Pompe disease (LOPD), affecting individuals over one year old, leads to trunk and proximal muscle weakness, often impacting…
Rasagiline 1 mg tablets slow the progression of Parkinson’s disease, according to Phase III trial data. From our partners at VerusMed VerusMed.com Sponsored by The Doctor’s Channel
The FDA has expanded indications for methylphenidate (Concerta) extended-release tablets to include adults aged 18 to 65 with ADHD. For more information visit: FDA Sponsored by The Doctor’s…
According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in…
The non-steroidal, anti-inflammatory drugs celecoxib and naproxen sodium do not improve cognitive function, ADAPT trial data indicate. From our partners at VerusMed: VerusMed.com Sponsored by The Doctor’s Channel
As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at…
New research indicates that treatment with the investigational anti-amyloid drug Tarenflurbil appears to be well-tolerated in patients with mild to moderate Alzheimer’s disease and may exert a dose-related…
In a recent study, fluoxetine (Prozac) decreased progression of relapsing-remitting MS in a small placebo-controlled study, but the effect lasted only a few months. References and Resources Mostert…
A tablet that combines sumatriptan and naproxen (Treximet) has been approved by the FDA for treatment of migraine with and without aura. References and Resources FDA Sponsored by…
Greg Foltz, MD, Director, Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, discusses current treatments for brain cancer. References and Resources Schönekaes K, Mücke R,…
Rituximab failed to meet the primary endpoint of stemming the progression of primary-progressive multiple sclerosis (PPMS) in a Phase II/III trial. From Our Partners at VerusMed verusmed.com Sponsored…
